Skip to main content

Table 1 Patients’ background

From: Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer

  Control group (n = 52) Aprepitant group (n = 54) P-value
Age (median, range) 59 (29–83) 58 (38–81) 0.70
Performance status (ECOG)
0–1/2–3
51/1 53/1 1.00
Cancer diagnosis (number, %)
 Ovarian or tubal cancer 17 (32.7) 22 (40.7) 0.43
 Uterine cancer 28 (53.8) 28 (51.9) 0.85
 Cervical cancer 6 (11.5) 1 (1.9) 0.06
 Vaginal cancer 0 (0) 1 (1.9) 1.00
 Double cancer 1 (1.9) 2 (3.7) 1.00
Staging (number, %)
 I/II/III 39 (75.0) 39 (72.2) 0.83
 IV/recurrence 13 (25.0) 15 (27.8)
Chemotherapy setting
 neoadjuvant or adjuvant 44 (84.6) 49 (90.7) 0.34
 for advanced cancer 8 (15.4) 5 (9.3)
Height (cm)
(median, range)
155.5 (144.6–172.1) 154.2 (142.0–169.5) 0.49
Body weight (kg)
(median, range)
54.7 (35.6–84.6) 54.3 (37.7–89.2) 0.79
Body surface area (m2)
(median, range)
1.53 (1.24–1.85) 1.54 (1.21–1.87) 0.90
Drinking habit (number, %) 24 (46.2) 21 (38.9) 0.57
Carboplatin dosage (AUC) (number, %)
 5 52 (100) 53 (98.1) 1.00
 6 0 (0) 1 (1.9)
Paclitaxel dosage (mg)
(median, range)
261.7 (220–320) 266.8 (210–325) 0.43
Dose reduction
(number, %)
3 (5.8) 1 (1.9) 0.36
Renal dysfunction
(number, %)
4 (7.6) 5 (9.3) 1.00
Liver dysfunction
(number, %)
9 (17.3) 12 (22.2) 0.63
  1. Renal dysfunction: grade 1 or higher serum creatinine elevation
  2. Liver dysfunction: grade 1 or higher aspartate transaminase, alanine aminotransferase, and total bilirubin elevation
  3. AUC area under the carve